What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Australasian Leukaemia & Lymphoma Group - ALLG

Home
Australia
Melbourne, VIC
Australasian Leukaemia & Lymphoma Group - ALLG

For patients, this means an improved chance of cure, and better quality of life.

Since 1973 the ALLG has been pioneering life-changing blood cancer clinical trials, delivering innovative treatment options that transform the lives of those with blood cancer. The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, collaborative clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 1,000 doctors, nurses, scientists and support staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers.

20/01/2026

Make 2026 a meaningful year and raise funds for leading, clinician-led blood cancer clinical trials right here in Australia. There are many ways you can get involved, with your support ensuring that ALLG’s leading researchers can deliver cutting edge research and the latest and best treatment options to blood cancer patients in need.

Now is your chance to become a champion for the 20,000+ people diagnosed annually with a blood cancer like leukaemia, lymphoma, or myeloma in Australia and New Zealand. Whether it’s a morning tea or a fun run, ALLG has a range of fun activities you can as a group or by yourself - head to our website to take a look at https://www.allg.org.au/support-us/fundraise-for-us/, or reach out to us at fundraising@allg.org.au for more info or to discuss your idea.

Support Research. Save Lives.

15/01/2026

The NBCR aims to help clinicians, researchers and policy makers to better understand the risk factors and causes of different blood cancers, including leukaemia, lymphoma and myelodysplastic syndromes (MDS). By capturing real-world, long-term data at different points in a patients’ blood cancer journey, including diagnosis, treatment, response and remission, the NBCR helps researchers to drive new research breakthroughs and deliver new treatments.

The NBCR now has data from over 5,000 blood cancer patients from across 49 participating hospitals, with 15 active research projects and studies underway to support new blood cancer treatments. The NBCR is fully integrated with ALLG’s clinical trial portfolio, acting as a pathway for patients to access current and future clinical trials for their blood cancer.

Your support is vital for the NBCR Registry to enable this important resource to grow and accelerate blood cancer research for Better treatments…Better lives. For more information, visit https://tinyurl.com/ms98n48n.

13/01/2026

From new clinical trial openings to major research presentations and practice-changing results, there's always important progress happening in blood cancer research. Our News page at https://www.allg.org.au/news/ features the latest updates, including new trials, research highlights, and key developments from scientists and clinicians shaping the future of blood cancer care and treatment. To stay up to date with the latest news from ALLG, you can also subscribe to our newsletter - https://www.allg.org.au/subscribe-to-allg-news/.

06/01/2026

As we step into 2026, ALLG members are focused on what matters most: delivering high-quality, evidence-based clinical trials that improve outcomes for people living with blood cancers.

This year, we are committed to:

-Expanding access to innovative and practice-changing clinical trials across Australia and New Zealand
-Generating high-quality evidence that informs best practice in blood cancer treatment
-Strengthening collaborations across our investigator network, hospital sites and research partners
-Supporting clinicians and researchers who drive research excellence and contribute to our shared mission
-Ensuring patients and families remain at the centre of everything we do

We look forward to another impactful year as we pursue Better treatments...Better lives for all people with blood cancer. For more information, visit allg.org.au.

30/12/2025

As we wrap up another huge year at the ALLG, we are reflecting on the year that’s been and looking forward to 2026.

With your support, ALLG has enabled 1,058 patients to access new and better treatments through our clinical trials. We also have 75+ active clinical trials researching innovative and life-saving treatment options across leukaemia, lymphoma and myeloma.

Another highlight of 2025 was the appointment of our second ALLG HSANZ Clinical Trials Fellow, Dr Safia Belbachir. Dr Belbachir’s project investigates how genetic variation (pharmacogenomics) influences the current treatment protocols and patient response in graft versus host disease (GVHD) in patients undergoing stem cell transplant. It's thanks to your generosity and support that ALLG is able to support game-changing blood cancer right here at home.

Every dollar that you have donated or fundraised this year has gone towards making this vital work possible. We look forward to working with you again in 2026 to advance blood cancer clinical trial research in Australia and New Zealand.

To learn more and find out how you can be involved, please visit us at: www.allg.org.au/support-us.

24/12/2025

From everyone here at ALLG, we wish you a restful and happy holidays!

We want to thank each and every one of you for your support of our clinical trials and blood cancer research this year.

Your support is vital to achieving our vision of a world where all blood cancers can be treated effectively and even cured.

To learn more about our work and how you can be involved, please visit: www.allg.org.au/support-us

23/12/2025

The CML11 PINNACLE Study, led by ALLG, explored whether combining targeted therapy with immune based-therapy treatment could help people newly diagnosed with chronic myeloid leukaemia (CML) achieve deeper, faster responses. This is important as deeper responses mean better long-term control of CML.

We're proud to see CML11 PINNACLE published in the British Journal of Haematology. Congratulations to Professor David Yeung, Professor Tim Hughes and the ALLG team for advancing care for people living with CML. Visit, allg.org.au for more information.

18/12/2025

ALLG's Early Career Clinician Researcher (ECCR) Program is opening for applications in early January, and we are inviting passionate emerging clinicians to be part of this exciting 2-year development opportunity.

Designed for trainees, registrars, fellows, and junior consultants with an interest in cancer and haematology research, this program provides:

-A place on the ALLG Scientific Advisory Committee

-Firsthand exposure to clinical trial design, conduct and oversight

-Opportunities to engage in real-world clinical trial research with the ALLG
Mentorship, learning, and professional growth within a research community

This initiative was created to empower the next generation of blood cancer clinician researchers. Applications open early January 2026 for ALLG Members - allg.org.au.

16/12/2025

It’s not too late to make a difference this Christmas in the lives of people with blood cancers like leukaemia, lymphoma, and myeloma. People like Stephanie, who at the height of the COVID-19 pandemic was dealt not one but two devastating blows. Her leukaemia was back and she was also facing the possibility of graft versus host disease (GVHD) as a side effect of her stem cell transplant. GVHD is a serious and sometimes fatal complication with devastating, irreversible effects on organs like the skin, eyes, mouth, lungs and gastrointestinal tract.

Hope came in the form of a clinical trial. The ALLG BM12 CAST trial, led by Professor David Curtis, which delivered a new treatment that tripled the chance of patients being alive, cancer free and free of GVHD 3 years after their stem cell transplant. Professor Curtis shares, “These results are game-changing for stem cell transplant patients, with the new treatment combination of cyclosporin and cyclophosphamide offering a new standard of care for prevention of GVHD for patients.”

These are great results, but we need to do more. With over 2000 patients in Australia and New Zealand requiring a stem cell transplant every year and 1 in 3 of these affected by GVHD, it is still having a devastating impact.

Please donate today so that ALLG’s researchers can continue doing what they do best - delivering Better treatments…Better lives for people with blood cancer. https://tinyurl.com/23r9pf95.

11/12/2025

We are thrilled to celebrate all our ALLG members who presented their research at the recent 2025 American Society of Hematology (ASH) Annual Meeting & Exposition. Their work in advancing blood cancer treatments through ALLG clinical trial research is helping shape the future of patient care. To find out more about ALLG’s blood cancer research, visit allg.org.au.

04/12/2025

A range of ALLG clinical trial abstracts have been accepted to the American Society of Hematology (ASH) Annual Meeting . This is recognition of our members' high-impact, groundbreaking research among thousands of submissions worldwide.

Clinical trials are key to advancing new, better treatments for patients with blood cancer. ALLG is proud to be leading the way, with over 75 active clinical trials across leukaemia, lymphoma and myeloma and a strong collaborative network with global cooperative research groups.

ALLG member research drives innovation in cancer care and progress toward our mission of Better treatments...Better lives for people with blood cancer. Visit, https://tinyurl.com/2s4m9a7p for more information.

02/12/2025

ALLG is the only not-for-profit blood cancer clinical trial group across Australia and New Zealand - and for over 50 years we have been relentlessly pursuing Better treatments…Better lives. Our work is powered by a strong network of haematologists, scientists and researchers working together to translate cutting-edge science into real-world impact.

Be a part of the breakthrough - donate to our world-leading research and help change the future of blood cancer treatment and care.

Address

Ground Floor, 35 Elizabeth Street
Melbourne, VIC
3121

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://www.allg.org.au/support-us/make-a-donation/

Alerts

Be the first to know and let us send you an email when Australasian Leukaemia & Lymphoma Group - ALLG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Australasian Leukaemia & Lymphoma Group - ALLG:

Shortcuts

Want your practice to be the top-listed Clinic in Melbourne?

Our Story

The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, investigator run clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 750 doctors, nurses, scientists and professional staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers. For patients, this means an improved chance of cure, and better quality of life.